Panic Not, Say Analysts As Apellis’s Syfovre Launch Is Beset By Retinal Vasculitis Events

Stock Down By 38%

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

The US firm’s Syfovre for geographic atrophy due to age-related macular degeneration was linked with a handful of cases of occlusive retinal vasculitis, according to a letter published by a top retinal society, but most analysts believe there is a reasonable explanation.  

3d graphic of cross-section of eye in doctor's hand
42% Of Eyes With Geographic Atrophy Are Classed As Legally Blind • Source: Shutterstock

Key Takeaways:

  • Six cases of occlusive retinal vasculitis occurred across a total of 6,000 injections.

Apellis Pharmaceuticals, Inc.’s Syfovre is taking the heat following the publication of a letter recommending doctors exercise caution after a few instances of a previously unseen safety event emerged in the real world setting, although several analysts remained unfazed and projected a continued successful launch.

Syfovre (pegcetacoplan) became the first and only US Food and Drug Administration-approved drug for the treatment of geographic atrophy secondary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Sensory

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

Acelyrin Belatedly Drops Izokibep In Its Lead Indications

 
• By Elizabeth Cairns

The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.  

Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

 
• By Mandy Jackson

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.